Nephrocare Health Services Limited has informed the Exchange regarding a press release dated May 19, 2026, titled "Please find attached herewith Press Release for the quarter and year ended March 31, 2026.".
NEPHROPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
NephroPlus reported strong FY26 results with revenue of Rs 998.8 crore, up 32.2% YoY, driven by 16.6% treatment volume growth and improved revenue per treatment of Rs 2,598 (up 13.3% YoY). Full year Adjusted EBITDA grew 37.6% to Rs 238.1 crore with EBITDA margin expanding 100 bps to 23.8%, while Adjusted PAT surged 74.6% to Rs 128.3 crore with margin improving 310 bps to 12.8%. A key highlight is the shift toward international markets, with their revenue contribution rising from 31.8% to 41.8%, which is more profitable. ROCE improved to 22.8% from 19.9% YoY. Q4 FY26 showed similar growth but with a 380 bps EBITDA margin contraction due to timing costs.
The company delivered robust full-year profitability improvement driven by volume growth and favorable geographic mix, with management emphasizing scalable platform benefits and balanced capital allocation. Q4 margin compression appears seasonal and does not threaten the overall positive FY27 outlook.